Meropenem Dosing for Pneumonia
For adults with hospital-acquired pneumonia (HAP) or ventilator-associated pneumonia (VAP), administer meropenem 1 gram IV every 8 hours as a 3-hour infusion, adjusting for renal function and pathogen susceptibility.
Adult Dosing
Standard Regimen for HAP/VAP
- Dose: 1 gram IV every 8 hours 1, 2
- Infusion duration: Administer as 3-hour infusion rather than bolus injection to maximize time above MIC 3
- Alternative: May give as 15-30 minute infusion or 3-5 minute bolus if extended infusion not feasible 2
Renal Impairment Adjustments (Adults)
Critical consideration: Meropenem is primarily renally cleared, requiring dose reduction in renal impairment 2, 4
| Creatinine Clearance | Dose | Interval |
|---|---|---|
| >50 mL/min | 1 gram | Every 8 hours |
| 26-50 mL/min | 1 gram | Every 12 hours |
| 10-25 mL/min | 500 mg | Every 12 hours |
| <10 mL/min | 500 mg | Every 24 hours |
Augmented Renal Clearance (ARC)
For critically ill patients with CrCL 140-200 mL/min, standard dosing is insufficient 5. Use 2 grams every 8 hours as 3-hour infusion to achieve adequate PK/PD targets for MIC ≤2 mg/L 5. For MIC 4-8 mg/L, consider continuous infusion or alternative therapy 5.
Continuous Renal Replacement Therapy (CRRT)
CRRT significantly increases meropenem clearance (2.1-fold compared to non-CRRT renal impairment) 4. Administer 500 mg every 6 hours as 3-hour infusion for patients on CRRT 4.
Pediatric Dosing
Children ≥3 Months with Normal Renal Function
The provided guidelines focus on community-acquired pneumonia in children and recommend third-generation cephalosporins (ceftriaxone/cefotaxime) as preferred agents, not meropenem 6. Meropenem is not a first-line agent for pediatric pneumonia per these guidelines.
However, FDA labeling provides dosing for complicated infections:
- Complicated skin/soft tissue infections: 10 mg/kg (max 500 mg) every 8 hours 2
- Intra-abdominal infections: 20 mg/kg (max 1 gram) every 8 hours 2
- Meningitis: 40 mg/kg (max 2 grams) every 8 hours 2
For pneumonia specifically, extrapolate from intra-abdominal dosing: 20 mg/kg every 8 hours (maximum 1 gram per dose) as 15-30 minute infusion 2.
Infants <3 Months
For complicated intra-abdominal infections (extrapolate for severe pneumonia):
| Age/Gestational Age | Dose | Interval |
|---|---|---|
| <32 weeks GA, PNA <2 weeks | 20 mg/kg | Every 12 hours |
| <32 weeks GA, PNA ≥2 weeks | 20 mg/kg | Every 8 hours |
| ≥32 weeks GA, PNA <2 weeks | 20 mg/kg | Every 8 hours |
| ≥32 weeks GA, PNA ≥2 weeks | 30 mg/kg | Every 8 hours |
Clinical Context and Caveats
When to Use Meropenem for Pneumonia
Meropenem is not first-line for community-acquired pneumonia in any age group 6. Reserve for:
- HAP/VAP with risk factors for multidrug-resistant organisms 1
- Documented infections with resistant Gram-negative pathogens
- Severe infections requiring broad-spectrum coverage pending cultures
Infusion Strategy
Extended infusion (3 hours) is superior to bolus injection 3. A study in VAP patients demonstrated that 3-hour infusion of 1 gram achieved T>MIC of 16 mg/L for 37.8% of the dosing interval versus 28.3% with bolus 3. For 2 gram doses, 3-hour infusion achieved 57.9% T>MIC at 16 mg/L 3.
PK/PD Target
Optimal bactericidal activity requires 40-100% fT>MIC depending on infection severity 7, 8. For critically ill patients or resistant pathogens (MIC ≥4 mg/L), target 100% fT>MIC with extended or continuous infusion 7, 5.
Combination Therapy
For HAP/VAP, meropenem monotherapy demonstrated superior efficacy (68.1% clinical response) compared to ceftazidime plus amikacin (54.9%) 9. However, current guidelines recommend combination therapy for high-risk patients 1.
Monitoring
No routine therapeutic drug monitoring required, but consider in: